文献速递脑血管病

替奈普酶与阿替普酶在远端及中等血管闭塞性卒中中的早期再通:观察性队列研究

Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study.
PubMed 文献 · Stroke · 2026-09-10

本研究为单中心观察性队列研究,纳入319例MRI确诊的远端及中等血管闭塞(DMVO)卒中患者,按机构方案分别接受阿替普酶(0.9 mg/kg,2016-2018年)或替奈普酶(0.25 mg/kg,2018-2023年)静脉溶栓。倾向评分加权分析显示,替奈普酶组早期成功再通率高于阿替普酶组(45.3% vs 33.1%,OR 1.59,95%CI 1.15-2.20,P=0.005),且早期梗死体积显著增长的风险更低(26.8% vs 40.5%,OR 0.49,95%CI 0.35-0.69,P<0.0001)。

要点

  • 替奈普酶组早期成功再通率45.3%,高于阿替普酶组的33.1%。
  • 替奈普酶组早期梗死体积显著增长风险低于阿替普酶组。
  • 研究结果支持在DMVO卒中优先使用替奈普酶进行静脉溶栓。

核心结论

  • 与阿替普酶相比,替奈普酶治疗的DMVO卒中患者早期成功再通率更高,且早期梗死体积显著增长的风险更低,支持在此类患者中优先使用替奈普酶。

研究设计与样本

  • 单中心观察性队列研究,纳入法国Centre Hospitalier Sud-Francilien连续收治的319例MRI确诊的DMVO卒中患者。
  • 按机构溶栓方案,159例接受替奈普酶0.25 mg/kg(2018-2023年),160例接受阿替普酶0.9 mg/kg(2016-2018年)。
  • 排除拟行血管内取栓或随访MRI质量不合格的患者,溶栓后1-2小时复查MRI。
  • 采用倾向评分加权校正年龄、性别、血管危险因素、基线NIHSS评分、闭塞部位及时间 period(2020-2023 vs 2016-2019)等基线不平衡。

主要发现

  • 替奈普酶组与阿替普酶组的中位基线NIHSS评分分别为3(1-7)和4(1-7.5),M2段闭塞分别占54.1%和43.8%。
  • 在溶栓后中位80(70-94)分钟评估,替奈普酶组72例(45.3%)和 rival 阿替普酶组53例(33.1%)达到早期成功再通(倾向评分加权OR 1.59,95%CI 1.15-2.20,P=0.005)。
  • 替奈普酶组42例(26.8%)和阿替普酶组64例(40.5%)出现早期梗死体积显著增长(倾向评分加权OR 0.49,95%CI 0.35-0.69,P<0.0001)。

关键数值与推荐

  • 早期成功再通定义为溶栓后早期随访MRI显示再通≥50%(改良动脉闭塞病变量表评分≥2b级)。
  • 早期梗死体积显著增长定义为半自动分割技术评估的病灶体积增加≥0.5 mL且≥20%。

临床怎么用

  • 对于MRI确诊的DMVO卒中患者,可考虑优先选用替奈普酶0.25 mg/kg进行静脉溶栓,以争取更高早期再通并减少早期梗死增长。

局限性

  • 本研究为单中心观察性队列研究,非随机对照设计,尽管采用倾向评分加权,仍可能存在残余混杂。
  • 研究仅纳入MRI确诊且完成早期随访MRI的患者,排除了拟行血管内取栓者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. METHODS: This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016-2018) or tenecteplase (0.25 mg/kg, 2018-2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020-2023 versus 2016-2019). RESULTS: Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1-7) in the tenecteplase group versus 4 (1-7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70-94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting-odds ratio, 1.59 [95% CI, 1.15-2.20]; P=0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting-odds ratio, 0.49 [95% CI, 0.35-0.69]; P<0.0001). CONCLUSIONS: Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05635786.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Chausson N, Benzakoun J, Vargas-Ibarra S, et al. Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study. Stroke. 2026. PMID: 42717910. doi:10.1161/STROKEAHA.125.054734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。